Topical prophylaxis for HIV prevention in women

Becoming a reality

Natasha A. Verma, Anna C. Lee, Betsy Herold, Marla J. Keller

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Strategies to protect against sexual transmission of HIV include the development of products formulated for topical application, which limit the toxicities associated with systemic oral pre-exposure prophylaxis. Following several clinical trial failures, attention is now focused on antiretroviral (ARV) agents. Highly potent ARV topical formulations provide a female-controlled, targeted, and feasible option for HIV prevention. A recently completed tenofovir gel trial was the first to demonstrate significant protection against HIV acquisition. Topical ARVs have the advantage of delivering high concentration of drug at the site of transmission of HIV, with low systemic absorption. Sustained-release formulations, such as intravaginal rings, will likely improve adherence and can be designed to provide controlled and continuous delivery of ARV combinations. Further studies to test alternative dosing strategies and pharmacokinetic/pharmacodynamic relationships in the genital tract will provide valuable information as the field strives to improve upon the promising tenofovir gel trial results.

Original languageEnglish (US)
Pages (from-to)104-113
Number of pages10
JournalCurrent HIV/AIDS Reports
Volume8
Issue number2
DOIs
StatePublished - Jun 2011

Fingerprint

Tenofovir
HIV
Gels
Anti-Retroviral Agents
Pharmacokinetics
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Adherence
  • Antiretroviral drugs
  • Biomarkers
  • Dapivirine
  • Genital tract
  • Herpes simplex virus
  • Human immunodeficiency virus
  • Intravaginal ring
  • Maraviroc
  • Pharmacodynamics
  • Pharmacokinetics
  • Pre-exposure prophylaxis
  • Tenofovir
  • Topical microbicides

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Topical prophylaxis for HIV prevention in women : Becoming a reality. / Verma, Natasha A.; Lee, Anna C.; Herold, Betsy; Keller, Marla J.

In: Current HIV/AIDS Reports, Vol. 8, No. 2, 06.2011, p. 104-113.

Research output: Contribution to journalArticle

@article{b96157263a43400d9a3ec35106f3262f,
title = "Topical prophylaxis for HIV prevention in women: Becoming a reality",
abstract = "Strategies to protect against sexual transmission of HIV include the development of products formulated for topical application, which limit the toxicities associated with systemic oral pre-exposure prophylaxis. Following several clinical trial failures, attention is now focused on antiretroviral (ARV) agents. Highly potent ARV topical formulations provide a female-controlled, targeted, and feasible option for HIV prevention. A recently completed tenofovir gel trial was the first to demonstrate significant protection against HIV acquisition. Topical ARVs have the advantage of delivering high concentration of drug at the site of transmission of HIV, with low systemic absorption. Sustained-release formulations, such as intravaginal rings, will likely improve adherence and can be designed to provide controlled and continuous delivery of ARV combinations. Further studies to test alternative dosing strategies and pharmacokinetic/pharmacodynamic relationships in the genital tract will provide valuable information as the field strives to improve upon the promising tenofovir gel trial results.",
keywords = "Adherence, Antiretroviral drugs, Biomarkers, Dapivirine, Genital tract, Herpes simplex virus, Human immunodeficiency virus, Intravaginal ring, Maraviroc, Pharmacodynamics, Pharmacokinetics, Pre-exposure prophylaxis, Tenofovir, Topical microbicides",
author = "Verma, {Natasha A.} and Lee, {Anna C.} and Betsy Herold and Keller, {Marla J.}",
year = "2011",
month = "6",
doi = "10.1007/s11904-011-0075-7",
language = "English (US)",
volume = "8",
pages = "104--113",
journal = "Nature Methods",
issn = "1548-7091",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Topical prophylaxis for HIV prevention in women

T2 - Becoming a reality

AU - Verma, Natasha A.

AU - Lee, Anna C.

AU - Herold, Betsy

AU - Keller, Marla J.

PY - 2011/6

Y1 - 2011/6

N2 - Strategies to protect against sexual transmission of HIV include the development of products formulated for topical application, which limit the toxicities associated with systemic oral pre-exposure prophylaxis. Following several clinical trial failures, attention is now focused on antiretroviral (ARV) agents. Highly potent ARV topical formulations provide a female-controlled, targeted, and feasible option for HIV prevention. A recently completed tenofovir gel trial was the first to demonstrate significant protection against HIV acquisition. Topical ARVs have the advantage of delivering high concentration of drug at the site of transmission of HIV, with low systemic absorption. Sustained-release formulations, such as intravaginal rings, will likely improve adherence and can be designed to provide controlled and continuous delivery of ARV combinations. Further studies to test alternative dosing strategies and pharmacokinetic/pharmacodynamic relationships in the genital tract will provide valuable information as the field strives to improve upon the promising tenofovir gel trial results.

AB - Strategies to protect against sexual transmission of HIV include the development of products formulated for topical application, which limit the toxicities associated with systemic oral pre-exposure prophylaxis. Following several clinical trial failures, attention is now focused on antiretroviral (ARV) agents. Highly potent ARV topical formulations provide a female-controlled, targeted, and feasible option for HIV prevention. A recently completed tenofovir gel trial was the first to demonstrate significant protection against HIV acquisition. Topical ARVs have the advantage of delivering high concentration of drug at the site of transmission of HIV, with low systemic absorption. Sustained-release formulations, such as intravaginal rings, will likely improve adherence and can be designed to provide controlled and continuous delivery of ARV combinations. Further studies to test alternative dosing strategies and pharmacokinetic/pharmacodynamic relationships in the genital tract will provide valuable information as the field strives to improve upon the promising tenofovir gel trial results.

KW - Adherence

KW - Antiretroviral drugs

KW - Biomarkers

KW - Dapivirine

KW - Genital tract

KW - Herpes simplex virus

KW - Human immunodeficiency virus

KW - Intravaginal ring

KW - Maraviroc

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Pre-exposure prophylaxis

KW - Tenofovir

KW - Topical microbicides

UR - http://www.scopus.com/inward/record.url?scp=79957530096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957530096&partnerID=8YFLogxK

U2 - 10.1007/s11904-011-0075-7

DO - 10.1007/s11904-011-0075-7

M3 - Article

VL - 8

SP - 104

EP - 113

JO - Nature Methods

JF - Nature Methods

SN - 1548-7091

IS - 2

ER -